Navigation Links
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Date:10/21/2008

"http://www.avidbio.com" target="_new">http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... 02, 2015 , ... Sleepless nights will become obsolete as Luzi , ... Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will love ... use, while the integration of the Bluetooth speaker, alarm clock and ability to charge ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to ... single photon emission computed tomography (SPECT) according to researchers from Amen Clinics, ... over 20,000 brain scans and is believed to be the largest brain imaging study ...
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... and BANGALORE, India , July ... profiling company that uses next generation sequencing technology to ... Scott A. Storrer as chief executive officer. In ... will be responsible for all strategy, business expansion and ... who has served as Strand,s chairman and CEO since ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... The U.S. Food and Drug Administration (FDA) has ... new technology: Cornell Dots, brightly glowing nanoparticles that can ... paper describing this new medical technology, "Multimodal silica nanoparticles ... melanoma," will be published June 13, 2011 in the ...
... Md., June 13, 2011 Spherix Incorporated ... innovator in biotechnology for therapy in diabetes, metabolic ... regulatory consulting services to food, supplement, biotechnology and ... Kruger, Chief Executive Officer, will present to investors ...
... Company (the "Company") (NYSE: KVa/KVb) today announced that it has ... 31, 2011 with the U.S. Securities and Exchange Commission. ... today at 4:30 p.m. EDT to discuss the Form 10-K ... matters. Participants can listen to the conference call by dialing ...
Cached Biology Technology:Glowing Cornell dots -- a potential cancer diagnostic tool set for human trials 2Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16 2Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16 3K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 2K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 3K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 4K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 5K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 6K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 7
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... The fascinating interactions between flowers and their pollinators ... In order to entice pollinators such as bees, ... their flowers, plants have evolved intriguing mechanisms and ... Thirty years ago, researchers discovered that nectars of ...
... typical of their species, the first known example after ... The discovery, reported in today's Nature, further supports the ... social relationships among animals that separate and reunite over ... , Researchers from the Amboseli Trust for Elephants in ...
... (UC) College of Medicine have discovered the cause of ... vasospasm. , A constriction of the blood vessels in ... days following a massive brain bleed known as hemorrhagic ... stroke develop vasospasm, and 40 percent of them die ...
Cached Biology News:Elephants imitate sounds as a form of social communication 2Researchers discover molecule that causes secondary stroke 2
Peptide-affinity Purified Polyclonal Antibody to Prolactin Releasing Hormone Receptor (GPR10)...
...
...
... data entry by collecting data from any ... Collect is extremely easy to use ... data entry. An excellent solution for ... spectrophotometers, force gauges, digital calipers, bar code ...
Biology Products: